Search

Now showing items 1-1 of 1

Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less

Özaslan, Ersin; Karaca, Halit; Koca, Sinan; Sevinç, Alper; Hacıoğlu, Bekir; Özkan, Metin; Dane, Faysal; Tanrıverdi, Özgür (Lippincott Williams & Wilkins, 2017)

The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were ...